M. (1996). BRCA1 testing: Some issues in moving from research to service. Psycho-Oncology, 5, 223-232.Ponder M, Green JM (1996): BRCA1 testing: Some issues in moving from research to service. Psycho-Oncology 5:223-232.Ponder M, Green JM. 1996. BRCA1 testing: some issues in ...
BRCA1基因突变的检测包括分子和表型检测方法。分子检测方法有基因测序（如聚合酶链反应（PCR）法、微量组...
BRCA1和BRCA2基因检测通常是通过血液或唾液样本获取DNA细胞来进行的。运用PCR技术，包括但不限于阴性外切...
首先需要明确的是这样一个事实:在家族性聚集的乳癌/卵巢癌患者中,患病人数越多、患者越年轻、乳癌和卵巢癌混合患病通常提示这个家族携带BRCA基因突变的可能性越高,然而,大多数家族性聚集的乳癌患者并非是由于BRCA1/2突变基因携带引起的。生殖系基因检测(germline genetic t...
Testing for inherited susceptibility to breast cancer: A survey of informed consent forms for BRCA1 and BRCA2 mutation testing Objective: To assess practicing and future physicians鈥 preparedness to obtain informed consent for cancer susceptibility testing. Methods: Questionnaires ... Sharon,J.,Durfy,...
Recently, it was proposed that all individuals below 50 years of age with TN breast cancer should be offered BRCA testing. We have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with TN breast cancer. METHODS: We undertook...
[1]Armstrong K, Weiner J, Weber B, Asch DA. Early adoption of BRCA1/2 testing: who and why. Genet Med. 2003;5(2):92-98. doi:10.1097/01.GIM.0000056829.76915.2A [2]Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1...
ARTICLE Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer Molly S. Daniels, MS1, Diana L. Urbauer, MS2, Jennifer L. Stanley, BS1, Kristin G. Johnson, BSN3, and Karen H. Lu, MD1 Purpose: To determine when, in reference to the course of their treatment, women with...
2018年9月25日,《Journal of the American Medical Association》期刊发表了这一篇题为“Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing”的文章,作者回顾145万人的遗传性癌症基因检测结果发现,近25%的“不确定重要性的基因突变”随后被重新分类——有些与癌症相关的可能性较低,有些...
对所有女性进行BRCA1/2基因突变检测是一种更具成本效益的策略。 文章来源:基因Talks 参考资料: 1.Manchanda Ranjit,Sun Li,Patel Shreeya et al. BRCA1/BRCA2Economic Evaluation of Population-Based Mutation Testing across Multiple Countries and Health Systems.[J] .Cancers (Basel), 2020, 12: undefined....